Jan. 14 at 3:52 PM
Hillstream BioPharma Inc.
$THAR
Developing drug candidate, HSB-1216, in solid tumors.
Data from a clinical pilot study in Germany led us to progress HSB-1216 into IND-enabling studies with the goal of submitting an IND to the FDA in 2022.
$THAR $PTX $PIXY $BSPM